ASIRI 2008.
Methods | Randomised, placebo‐controlled, double‐blind trial |
Participants | People with SMA types II or III, aged 6–20 years. |
Interventions | Riluzole 50 mg/day orally or placebo Duration of treatment: 24 months Follow‐up: 24 months |
Outcomes | Motor function (MFM scale), spirometry (FVC), Measure of Functional Independence, adverse events and tolerance evaluation. |
Notes | Study completed (December 2011), but no results available. |